当前位置: X-MOL 学术Drug Test. Anal. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Detection of a nonerythropoietic erythropoietin, Neuro-EPO, in blood after intranasal administration in rat.
Drug Testing and Analysis ( IF 2.6 ) Pub Date : 2020-08-27 , DOI: 10.1002/dta.2924
Laurent Martin 1 , Julio Cesar Garcia Rodriguez 2 , Michel Audran 1 , Magnus Ericsson 1 , Tangui Maurice 3 , Alexandre Marchand 1
Affiliation  

Nonerythropoietic erythropoietins (EPOs) are investigated for their high antioxidant properties. A new drug candidate under clinical investigation to treat brain diseases is Neuro‐EPO, produced by selecting EPO isoforms with low sialic acid content. Intranasal administration allows to bypass the blood–brain barrier to get a fast and concentrated delivery to the brain. The aims of this project were to characterize Neuro‐EPO with anti‐doping methods used to detect conventional recombinant EPOs (isoelectric focusing [IEF] and sodium dodecyl sulfate–polyacrylamide gel electrophoresis [SDS‐PAGE]) and to evaluate the window of detection of Neuro‐EPO in brain and blood (plasma) after a single intranasal administration in rats. Neuro‐EPO drug analyzed by IEF‐PAGE presented a very basic profile completely detected only when using a 2–8 or 2–10 pH gradient instead of the conventional 2–6 pH gradient. Its profile consisted in six main bands that did not interfere with endogenous EPO profile from human or rat. After SDS‐PAGE, a broad band was detected for Neuro‐EPO in the same area as endogenous EPO, making Neuro‐EPO identification very difficult by this approach. Therefore, IEF was the method for identification chosen after administration in rats. Neuro‐EPO was clearly identified in blood 2 and 6 h after the delivery. Fainter signals were obtained between 12 and 48 h, but some characteristic very basic bands remained detectable. Surprisingly, brain extracts did not show the presence of Neuro‐EPO even 2 h after administration, indicating a fast degradation or elimination from the brain to the bloodstream. This experiment indicated that detection of Neuro‐EPO after intranasal delivery should be possible for a few days.

中文翻译:

在大鼠鼻内给药后检测血液中的非红细胞生成素,神经-EPO。

非红细胞生成性红细胞生成素 (EPO) 因其高抗氧化特性而受到研究。正在临床研究的一种治疗脑部疾病的新候选药物是 Neuro-EPO,它是通过选择低唾液酸含量的 EPO 同工型产生的。鼻内给药可以绕过血脑屏障,快速、集中地输送到大脑。该项目的目的是使用用于检测常规重组 EPO 的反兴奋剂方法(等电聚焦 [IEF] 和十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳 [SDS-PAGE])表征 Neuro-EPO,并评估检测窗口大鼠单次鼻内给药后大脑和血液(血浆)中的神经 EPO。通过 IEF-PAGE 分析的 Neuro-EPO 药物呈现出非常基本的特征,只有在使用 2-8 或 2-10 pH 梯度而不是传统的 2-6 pH 梯度时才能完全检测到。它的分布由六个主要条带组成,这些条带不干扰来自人类或大鼠的内源性 EPO 分布。SDS-PAGE 后,在与内源性 EPO 相同的区域检测到神经-EPO 的宽条带,使得通过这种方法鉴定神经-EPO 变得非常困难。因此,IEF是大鼠给药后选择的鉴定方法。分娩后 2 小时和 6 小时,在血液中清楚地识别出 Neuro-EPO。在 12 到 48 小时之间获得了较暗的信号,但仍然可以检测到一些特征性的非常基本的波段。令人惊讶的是,即使在给药后 2 小时,脑提取物也没有显示出 Neuro-EPO,表明从大脑到血液的快速降解或消除。该实验表明,鼻内给药后几天内应该可以检测到 Neuro-EPO。
更新日期:2020-08-27
down
wechat
bug